Slingshot Insights

Catalyst

Slingshot members are tracking this event:

AstraZeneca (AZN) aiming for 2018 data readout for NEPTUNE trial evaluating the ability of combination of durva and treme to treat lung cancer against current standard of care

Source Link:: https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_presentation.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AZN

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Aug 21, 2019

Occurred Source:

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Durva + Treme, Lung Cancer, Standard Of Care, Neptune